Analysis-Older Americans left out of costly GLP-1 craze expected to flock to new program

Medicare begins an 18-month trial on Wednesday that will cover obesity drugs Wegovy, Founda(y)o and Zepbound for eligible patients aged 65+ at $50/month, expanding access versus prior co-condition-only coverage. Eligibility is estimated in the single-digit millions, which Wall Street expects could translate into billions of dollars in incremental revenue for Novo Nordisk and Eli Lilly. Reuters also flags implementation friction (slow/complicated prior authorization) and the key risk that coverage may not extend beyond 2027.

Analysis

This is a step-function de-risking for the obesity franchise, but the market should separate eligibility from monetization. The first-order pop is justified; the second-order question is how much volume actually clears prior auth, how fast pharmacies stock, and whether adherence in an older cohort is durable enough to matter to 2025-26 consensus numbers. In that sense, the near-term earnings delta is probably smaller than the TAM headline suggests.

Among beneficiaries, LLY looks like the cleaner lever because incremental U.S. access should reinforce its lead position where share and physician momentum already matter most. NVO also benefits, but the market is more likely to punish any sign that it is gaining access into a structurally more promotional, lower-price channel rather than converting that demand into durable margin expansion. The bigger losers are cash-pay/compounded GLP-1 channels and any adjacent obesity services that depended on high out-of-pocket friction.

The contrarian miss is duration: a temporary pilot can create a burst of starts without proving long-term reimbursement, and older patients may discontinue faster if GI side effects or muscle-loss concerns surface. Over 1-3 months, the key catalyst is enrollment and prescription-fill data; over 6-18 months, the real test is whether commercial payers follow CMS or treat this as a one-off. If utilization lags while shares run, the setup shifts from fundamental upgrade to valuation compression.

Key Decisions for Investors

• Go long LLY on pullbacks over the next 1-2 weeks; best risk/reward is if the stock consolidates after the initial gap and management later confirms obesity revenue acceleration into Q3/Q4.
• Prefer LLY over NVO as a relative-value expression for the next 3-6 months; thesis breaks if NVO shows materially better U.S. access conversion or supply normalization while LLY usage stalls.
• Use call spreads rather than outright longs for NVO into the 1-3 month catalyst window; upside is real, but the market may have already priced part of the access benefit and implementation risk is high.
• Set a watch item on Medicare enrollment/fill data and clinician prior-auth turnaround times; if conversion is still slow after 30-60 days, fade the move because the policy headline is bigger than the revenue delta.
• No direct trade in REFI from this catalyst; the read-through is too indirect unless there is evidence of balance-sheet stress or capital-market spillover in healthcare finance.